Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07467772 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Ph 2 Elacestrant in ER Positive Uterine Sarcomas

Name: Ph 2 Elacestrant in ER Positive Uterine Sarcomas — clinical trial record (NCT07467772)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2

SponsorDana-Farber Cancer Institute

Started2026-03-25

View on ClinicalTrials.gov ↗

Amendment history

2026-05-21

Study Status, Contacts/Locations v2

Start date2026-04-15→2026-03-25

Study sitescontacts updated at 1 of 1 site

2026-04-20

Study Status, Contacts/Locations v1

Recruitment opened

Start dateestimated 2026-02→confirmed 2026-04-15

Study sites2→1

2026-03-09

Original filing

Dana-Farber Cancer Institute

287 trials monitored

See 33 trials at risk

Sarcoma

947 trials monitored

See 53 trials at risk

This study is to evaluate the efficacy and safety of elacestrant, in participants with advanced estrogen receptor (ER)-positive uterine sarcomas. The name of the study drug involved in this research study is: -Elacestrant (a type of selective estrogen receptor degrader)

Trial Details

NCT Number	NCT07467772
Lead Sponsor	Dana-Farber Cancer Institute Collaborators: Stemline Therapeutics, Inc.
Conditions	Uterine Sarcoma, Uterine Leiomyosarcoma, Endometrial Stromal Sarcoma, ESS, Perivascular Epithelioid Cell Tumors, Uterine Adenosarcoma, Uterine PEComa, Estrogen Receptor Positive Tumor +1 more
Enrollment	30 participants
Start Date	2026-03-25
Primary Completion	2027-07 (estimated)
Study Completion	2028-04 (estimated)
Updated on ClinicalTrials.gov	2026-05-22